Joanna Goldberg PhD
Overview
The Goldberg laboratory focuses on the strategies used by bacteria to cause diseases in humans, in particular respiratory infections in individuals with the genetic disease cystic fibrosis. We study various bacterial factors, especially surface polysaccharides and other potential adhesins. We assess their contribution to virulence and the physiology of the bacterium and their effects on host. We also examine and dissect essential metabolic pathways in these bacteria as targets for the development of novel therapeutics and vaccines to combat naturally antibiotic-resistant pathogens.
See also: https://scholarblogs.emory.edu/goldberglab/
Academic Appointment
- Professor, Division of Pulmonology, Allergy/Immunology, Cystic Fibrosis, and Sleep, Emory University School of Medicine
Education
Degrees
- BA from Boston University
- PhD from University of California
Research
Focus
- Dr. Goldbergs research is focused on mechanisms of bacterial pathogenesis. In particular, she studies bacteria that cause life-shortening lung infections in individuals with cystic fibrosis (CF). The goal of this work is to develop new approaches to inhibit these infections and thereby improve the quality of life of CF patients.
Publications
-
A fluorescence-based protocol to monitor bacterial antagonism.
Microbiol Spectr Page(s): e0318324
06/12/2025 Authors: Luu JM; Crisan CV; Pettis ML; Facio AR; Read TD; Goldberg JB -
Temperature controls LasR regulation of piv expression in Pseudomonas aeruginosa.
mBio Volume: 16 Page(s): e0054125
06/11/2025 Authors: Robinson RE; Robertson JK; Prezioso SM; Goldberg JB -
piv does not impact Pseudomonas aeruginosa virulence in Galleria mellonella.
Microbiol Spectr Page(s): e0281124
05/21/2025 Authors: Robinson RE; Robertson JK; Moustafa DA; Goldberg JB -
The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota.
Microbiology (Reading) Volume: 171
04/01/2025 Authors: Robertson JK; Goldberg JB -
R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa.
NPJ Antimicrob Resist Volume: 3 Page(s): 17
02/28/2025 Authors: Mei M; Estrada I; Diggle SP; Goldberg JB -
RNA-seq reproducibility of Pseudomonas aeruginosa in laboratory models of cystic fibrosis.
Microbiol Spectr Volume: 13 Page(s): e0151324
01/07/2025 Authors: Duncan RP; Lewin GR; Cornforth DM; Diggle FL; Kapur A; Moustafa DA; Hilliam Y; Bomberger JM; Whiteley M; Goldberg JB -
The dominant lineage of an emerging pathogen harbours contact-dependent inhibition systems.
Microb Genom Volume: 11
01/01/2025 Authors: Crisan CV; Goldberg JB -
Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.
Vaccine Volume: 42 Page(s): 126476
12/02/2024 Authors: Moustafa DA; Lou E; Schafer-Kestenman ME; Mateu-Borrs M; Domnech-Sanchez A; Albert S; Goldberg JB -
Serotype switching in Pseudomonas aeruginosa ST111 enhances adhesion and virulence.
PLoS Pathog Volume: 20 Page(s): e1012221
12/01/2024 Authors: Anbo M; Lubna MA; Moustafa DA; Paiva TO; Serioli L; Zor K; Sternberg C; Jeannot K; Ciofu O; Dufrne YF -
Intraspecific Diversity of Staphylococcus aureus Populations Isolated from Cystic Fibrosis Respiratory Infections.
11/16/2024 Authors: Alexander AM; Loo HQ; Askew L; Raghuram V; Read TD; Goldberg JB